Exophthalmos (Graves' Ophthalmopathy) - RAI vs. Thyroid Surgery

The Core Issue

Radioactive Iodine (RAI) - Effect on Exophthalmos

• RAI can worsen Graves' ophthalmopathy, especially in smokers - Cummings Otolaryngology Head & Neck Surgery explains this occurs "secondary to the development of tissue edema and worsening of the ocular symptoms" following RAI administration.
• The mechanism involves a post-ablation surge in TSH receptor antibodies (TRAb) - RAI destroys thyroid tissue, releasing thyroid antigens and transiently boosting the autoimmune response, which drives further orbital inflammation.
• Smokers are at significantly higher risk of RAI-induced ophthalmopathy worsening and should particularly avoid RAI if eye disease is present.
• RAI is not recommended in patients with moderate-to-severe Graves' ophthalmopathy, per Goldman-Cecil Medicine.

Thyroid Surgery - Effect on Exophthalmos

• Surgery is the preferred treatment when Graves' ophthalmopathy is moderate or severe. As stated in Cummings Otolaryngology, "an additional relative indication for surgery, as opposed to radioactive iodine, is moderate or severe ocular symptoms related to Graves ophthalmopathy, which may be worsened with radioactive iodine administration."
• KJ Lee's Otolaryngology lists as an indication for surgery: "concern regarding RAI and eye disease"
• Surgery does not trigger the same TSH receptor antibody surge as RAI, so it avoids the acute worsening mechanism.
• Berek & Novak's Gynecology notes: "Surgical intervention may be considered in severe Graves' ophthalmopathy. Surgery is the most rapid and consistent method of achieving a euthyroid state in Graves' disease."
• Achieving euthyroidism rapidly by surgery may actually stabilize the ophthalmopathy compared to the prolonged exposure to thyroid hormone excess while waiting for RAI to take effect (RAI typically takes 6-8 weeks to normalize thyroid hormone levels).

Summary Table

Recent Evidence (2024 Meta-Analysis)

• Thyroidectomy was associated with a 69% lower risk of Graves' ophthalmopathy vs. antithyroid drugs (HR 0.31, 95% CrI: 0.12-0.64) and an 82% lower risk vs. RAI (HR 0.18, 95% CrI: 0.07-0.35)
• RAI had a 70% higher risk of Graves' ophthalmopathy compared to antithyroid drugs (HR 1.70, 95% CrI: 1.02-2.99)
• This is the strongest current evidence confirming surgery as the ophthalmopathy-sparing treatment

Clinical Bottom Line

Before MTP: assess urgently

• Resting heart rate, blood pressure, temperature, tremor, agitation, diarrhea/vomiting, heart failure symptoms
• ECG if tachycardic or palpitations
• Repeat thyroid tests if needed: TSH, FT4, FT3, preferably thyroid receptor antibodies if Graves is suspected
• Cause of thyrotoxicosis: Graves, toxic nodule, thyroiditis, excess thyroid hormone, or molar pregnancy/high hCG state
• Ultrasound and pregnancy assessment as appropriate, particularly if severe vomiting, uterine size discrepancy, very high hCG, or bleeding suggests molar pregnancy

Practical approach

1. If MTP is elective and the patient is symptomatic or tachycardic

• No fever, agitation, heart failure, or active severe thyrotoxic symptoms
• Resting HR generally below 90/min
• FT4 controlled or normalizing. TSH may remain suppressed for 4-6 weeks after biochemical improvement, so it should not be the immediate clearance target. Miller's Anesthesia, p. 4250.

2. Control adrenergic symptoms

3. Use an antithyroid drug if this is Graves disease or another hormone-overproduction state

• In a continuing first-trimester pregnancy, PTU is generally preferred because methimazole exposure in early pregnancy is associated with congenital anomalies.
• If termination is imminent, the exact drug and timing should still be directed by endocrinology/obstetrics, considering liver function, gestational age, and the likely cause.
• Antithyroid drugs are not useful for thyroiditis or exogenous thyroid hormone use, because those states do not involve new hormone synthesis.

4. If MTP cannot be delayed

1. Thionamide first
2. Iodide only after thionamide has been started to block hormone release, not before it
3. Beta-blockade for heart-rate control
4. Glucocorticoid in severe thyrotoxicosis or concern for storm
5. IV fluids, temperature control, treat infection, minimize pain/anxiety, and close peri-procedural monitoring

When MTP should be deferred unless life-saving

• Fever
• HR persistently >120-130/min or atrial fibrillation
• Delirium, marked agitation, psychosis, or confusion
• Vomiting/diarrhea with dehydration
• Jaundice or hepatic dysfunction
• Pulmonary edema, heart failure, chest pain, hypotension
• Severe uncontrolled hypertension or infection

Bottom line

Drug-specific effects

Mifepristone

• No established clinically meaningful acute effect on FT3, FT4, or TSH after the usual single dose used for medical abortion.
• It is a progesterone-receptor antagonist and also has glucocorticoid-receptor antagonism. This is relevant mainly with chronic high-dose mifepristone used for Cushing syndrome, not standard abortion dosing.
• An animal study suggesting increased thyroid hormones after mifepristone is not enough to infer a risk in humans.
• There is no reliable human evidence that mifepristone itself causes thyroid storm.

Misoprostol

• Misoprostol does not stimulate thyroid hormone synthesis or release.
• Its common effects can be problematic in uncontrolled hyperthyroidism because they can overlap with, obscure, or potentially trigger decompensation:
  • fever/chills
  • tachycardia or palpitations
  • nausea, vomiting, diarrhea, dehydration
  • pain, anxiety, and uterine bleeding

What this means for a patient with T3-toxicosis

• afebrile
• alert and not agitated
• without vomiting/diarrhea or dehydration
• HR controlled, ideally below 90/min
• without atrial fibrillation, heart failure, or severe hypertension

Risk-reduction plan

1. Confirm cause and severity: pulse, temperature, ECG, FT3/FT4/TSH, clinical assessment for Graves disease, cardiac disease, and molar pregnancy if suspected.
2. Treat actual hyperthyroidism when indicated: antithyroid medication is appropriate for Graves disease/toxic nodular disease, but not for thyroiditis or exogenous thyroid hormone exposure.
3. Short-term beta-blockade for troubling tachycardia/tremor, if no contraindication. It treats symptoms but does not independently prevent thyroid storm. Barash Clinical Anesthesia, p. 3993.
4. Use a monitored setting rather than unsupervised/home abortion if overt hyperthyroidism is active or control is uncertain.
5. Ensure hydration, effective analgesia, assessment for anemia/bleeding risk, and clear access to emergency care.
6. Avoid radioactive iodine in pregnancy.

Treat as an emergency if any of these occur

• fever with HR >120-130/min
• severe agitation, confusion, delirium
• persistent vomiting/diarrhea or dehydration
• breathlessness, chest pain, fainting, pulmonary edema
• atrial fibrillation
• heavy bleeding, hypotension, or suspected sepsis

In medical abortion

• pre-existing uncontrolled thyrotoxicosis
• pain, anxiety, fever, dehydration, heavy bleeding, or infection during the process
• misoprostol effects, especially fever, chills, diarrhea, and tachycardia

With long-term/high-dose mifepristone

• Mifepristone has occasionally been associated with hypothyroidism or an increased levothyroxine requirement.
• Evidence is limited. A reported case developed reversible hypothyroidism during chronic mifepristone, resolving after it was discontinued (case report, PMID 37565673).
• It may be particularly relevant in patients with central hypothyroidism on thyroid replacement.

Bottom line for your hyperthyroid patient

• A single MTP dose of mifepristone is not expected to worsen FT3/FT4 or precipitate thyroid storm directly.
• If the patient has symptomatic or uncontrolled T3-toxicosis, stabilize clinically first, especially tachycardia, dehydration, fever, arrhythmia, or heart failure risk.
• Check pulse, temperature, symptoms, and consider ECG. Treat the underlying hyperthyroidism appropriately rather than withholding mifepristone solely because of low TSH.

• Misoprostol can cause transient fever/chills, pain, nausea, vomiting, diarrhea, and dehydration.
• It can sometimes be associated with tachycardia, especially when fever, pain, bleeding, or dehydration occur.
• These features can resemble, mask, or contribute to decompensation in a patient with poorly controlled thyrotoxicosis. They are not evidence that misoprostol worsens thyroid hormone levels.

In a patient with hyperthyroidism undergoing MTP

• Controlled, clinically stable hyperthyroidism: misoprostol is not contraindicated solely due to hyperthyroidism.
• Uncontrolled/symptomatic hyperthyroidism: use a supervised setting and stabilize tachycardia and dehydration first. Consider endocrinology and anaesthesia input.
• A short-lived mild fever/chills after misoprostol can be expected. But persistent fever, severe tachycardia, confusion/agitation, breathlessness, persistent vomiting/diarrhea, or heavy bleeding requires urgent hospital assessment for infection, hemorrhage, or thyroid storm.

Gilbert syndrome

• Liver cells are otherwise normal.
• Liver enzymes, ALP, albumin, and INR are normal.
• There is no hemolysis.
• It does not cause cirrhosis, liver failure, or require treatment. Sleisenger and Fordtran's Gastrointestinal and Liver Disease, p. 336.

Typical pattern

• Mild yellow eyes or skin that comes and goes
• Predominantly indirect bilirubin elevation, commonly below about 3-4 mg/dL
• Usually discovered incidentally on a blood test
• Normal prognosis and normal life expectancy

Common triggers for higher bilirubin

• Fasting or poor oral intake
• Dehydration
• Fever, infection, or another acute illness
• Physical exertion, stress, lack of sleep
• Menstruation
• Alcohol

Diagnosis

• Repeated isolated indirect bilirubin elevation
• Normal AST/ALT, ALP, and other liver-function markers
• Normal CBC, reticulocyte count, and blood film, excluding hemolysis

Medicines

• Irinotecan can cause greater toxicity because its metabolite relies on UGT1A1 metabolism.
• Some drugs, such as atazanavir, can raise indirect bilirubin.

Relevance to mifepristone-misoprostol / MTP